Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)

被引：0
|
作者：
Dasari, A. [1 ]
Paulson, S. [2 ]
Sung, M. [3 ]
Tucci, C. [4 ]
Kauh, J. [4 ]
Kania, M. [4 ]
Li, D. [5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Baylor Charles A Sammons Canc Ctr Texas Oncol, Dallas, TX USA
[3] Mt Sinai Hosp, New York, NY USA
[4] Hutchison MediPharma Int Inc, Florham Pk, NJ USA
[5] City Hope Canc Ctr, Duarte, CA USA
来源：
NEUROENDOCRINOLOGY | 2020年 / 110卷
关键词：
neuroendocrine tumors; pancreatic; surufatinib;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I02
引用
收藏
页码：209 / 209
页数：1
相关论文
共 50 条
  • [41] Next-Generation Sequencing (NGS) in Pancreatic Neuroendocrine Tumors (panNETs): Defining Differentiation and Grade Genetically
    Raj, Nitya
    Hrabovsky, Anastasia
    Alexander, Derek
    Shah, Ronak
    Baturk, Olca
    Tang, Laura
    Klimstra, David
    Reidy-Lagunes, Diane
    PANCREAS, 2017, 46 (03) : 432 - 432
  • [42] Can Neutrophil-to-Lymphocyte Ratio (NLR) Predict Clinical Outcomes of Pancreatic Neuroendocrine Tumors (PanNETs)?
    Massironi, S.
    Rossi, R. E.
    Ciafardini, C.
    Zilli, A.
    Cavalcoli, F. A.
    Giunta, M.
    Conte, D.
    NEUROENDOCRINOLOGY, 2018, 106 : 102 - 102
  • [43] Pattern and Clinical Predictors of Lymph Node Involvement in Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNETs)
    Partelli, Stefano
    Gaujoux, Sebastien
    Boninsegna, Letizia
    Cherif, Rim
    Crippa, Stefano
    Couvelard, Anne
    Scarpa, Aldo
    Ruszniewski, Philippe
    Sauvanet, Alain
    Falconi, Massimo
    JAMA SURGERY, 2013, 148 (10) : 932 - 939
  • [44] Next-generation sequencing (NGS) in pancreatic neuroendocrine tumors (panNETs): Defining differentiation and grade genetically
    Raj, Nitya Prabhakar
    Klimstra, David
    Shah, Ronak
    Osoba, Muyinat
    Alexander, Derek
    Reidy, Diane Lauren
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [45] Progression of pancreatic neuroendocrine tumors (PanNETs) to metastatic disease is associated with MCT4 expression and metabolic heterogeneity
    Sadowski, M.
    Brautigam, K.
    Straub, J.
    Andreasi, V
    Kirchner, P.
    Maire, R.
    Dettmer, M.
    Schrader, J.
    Partelli, S.
    Falconi, M.
    Marinoni, I
    Perren, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 149 - 149
  • [46] Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)
    Xu, Jianming
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [47] Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety
    La Salvia, Anna
    Bellino, Stefania
    Fanciulli, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (02) : 115 - 118
  • [48] Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
    Kansal, A.
    Chao, R.
    Patyna, S.
    Scheijbeler, H.
    Klok, R.
    Sandin, R.
    Sorensen, S.
    NEUROENDOCRINOLOGY, 2012, 96 : 39 - 39
  • [49] The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study
    Long, J.
    Wu, C.
    Hu, B.
    Tao, C.
    Gu, H.
    Dong, H.
    Yan, J.
    Qi, Z.
    Zhao, C.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S958 - S958
  • [50] Efficacy and safety of surufatinib in unresectable or metastatic grade 3 pancreatic neuroendocrine tumors (NET G3): Real-world analysis.
    Wang, Jian
    Liang, Yun
    Long, Jiang
    Chi, Yihebali
    Zhang, Suzhen
    Wu, Yinying
    Wang, Yu
    Bai, Chunmei
    Hu, Weiyu
    Hu, Hanguang
    Zhang, Lin
    Chen, Jie
    Hao, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 657 - 657
12345